|
1
|
Falzone L, Scandurra G, Lombardo V,
Gattuso G, Lavoro A, Distefano AB, Scibilia G and Scollo P: A
multidisciplinary approach remains the best strategy to improve and
strengthen the management of ovarian cancer (Review). Int J Oncol.
59:532021. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bray F, Laversanne M, Sung H, Ferlay J,
Siegel RL, Soerjomataram I and Jemal A: Global cancer statistics
2022: GLOBOCAN estimates of incidence and mortality worldwide for
36 cancers in 185 countries. CA Cancer J Clin. 74:229–263. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Stuart GC, Kitchener H, Bacon M, duBois A,
Friedlander M, Ledermann J, Marth C, Thigpen T and Trimble E;
participants of 4th Ovarian Cancer Consensus Conference (OCCC);
Gynecologic Cancer Intergroup, : 2010 gynecologic cancer InterGroup
(GCIG) consensus statement on clinical trials in ovarian cancer:
Report from the fourth ovarian cancer consensus conference. Int J
Gynecol Cancer. 21:750–755. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Daly MB, Pal T, Maxwell KN, Churpek J,
Kohlmann W, AlHilli Z, Arun B, Buys SS, Cheng H, Domchek SM, et al:
NCCN Guidelines® insights: Genetic/Familial high-risk
assessment: Breast, ovarian, and pancreatic, version 2.2024. J Natl
Compr Canc Netw. 21:1000–1010. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Friedlander M, Trimble E, Tinker A,
Alberts D, Avall-Lundqvist E, Brady M, Harter P, Pignata S,
Pujade-Lauraine E, Sehouli J, et al: Clinical trials in recurrent
ovarian cancer. Int J Gynecol Cancer. 21:771–775. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Markman M, Rothman R, Hakes T, Reichman B,
Hoskins W, Rubin S, Jones W, Almadrones L and Lewis JL Jr:
Second-line platinum therapy in patients with ovarian cancer
previously treated with cisplatin. J Clin Oncol. 9:389–393. 1991.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
St Laurent J and Liu JF: Treatment
approaches for platinum-resistant ovarian cancer. J Clin Oncol.
42:127–133. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kyrgiou M, Salanti G, Pavlidis N,
Paraskevaidis E and Ioannidis JP: Survival benefits with diverse
chemotherapy regimens for ovarian cancer: Meta-analysis of multiple
treatments. J Natl Cancer Inst. 98:1655–1663. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Havasi A, Cainap SS, Havasi AT and Cainap
C: Ovarian cancer-insights into platinum resistance and overcoming
it. Medicina (Kaunas). 59:5442023. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
McMullen M, Madariaga A and Lheureux S:
New approaches for targeting platinum-resistant ovarian cancer.
Semin Cancer Biol. 77:167–181. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Khan MA, Vikramdeo KS, Sudan SK, Singh S,
Wilhite A, Dasgupta S, Rocconi RP and Singh AP: Platinum-resistant
ovarian cancer: From drug resistance mechanisms to liquid
biopsy-based biomarkers for disease management. Semin Cancer Biol.
77:99–109. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Pennington KP, Walsh T, Harrell MI, Lee
MK, Pennil CC, Rendi MH, Thornton A, Norquist BM, Casadei S, Nord
AS, et al: Germline and somatic mutations in homologous
recombination genes predict platinum response and survival in
ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer
Res. 20:764–775. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Colombo PE, Taoum C, Fabbro M, Quesada S,
Rouanet P and Ray-Coquard I: Impact of molecular testing on the
surgical management of advanced epithelial ovarian cancer. Crit Rev
Oncol Hematol. 202:1044692024. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Saito YD, Jensen AR, Salgia R and Posadas
EM: Fyn: A novel molecular target in cancer. Cancer. 116:1629–1637.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Li S, Liu C and Tang Y: Role of Fyn in
hematological malignancies. J Cancer Res Clin Oncol. 149:6759–6767.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Nanno S, Fukuda T, Noda T, Uchikura E,
Awazu Y, Imai K, Yamauchi M, Yasui T and Sumi T: Fyn expression is
associated with the response of patients with locally advanced
uterine cervical squamous cell carcinoma to neoadjuvant
chemotherapy. Mol Clin Oncol. 17:1472022. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sinicrope FA, Ruan SB, Cleary KR, Stephens
LC, Lee JJ and Levin B: bcl-2 and p53 oncoprotein expression during
colorectal tumorigenesis. Cancer Res. 55:237–241. 1995.PubMed/NCBI
|
|
18
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
O'Malley DM, Krivak TC, Kabil N, Munley J
and Moore KN: PARP inhibitors in ovarian cancer: A review. Target
Oncol. 18:471–503. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Fukuda T, Noda T, Uchikura E, Awazu Y,
Tasaka R, Imai K, Yamauchi M, Ichimura T, Yasui T and Sumi T:
Real-world efficacy and safety of bevacizumab for advanced or
recurrent müllerian cancer: A single-institutional experience.
Anticancer Res. 43:3097–3105. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Friedlander ML, Stockler MR, Butow P, King
MT, McAlpine J, Tinker A and Ledermann JA: Clinical trials of
palliative chemotherapy in platinum-resistant or -refractory
ovarian cancer: Time to think differently? J Clin Oncol.
31:23622013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Dasari S and Tchounwou PB: Cisplatin in
cancer therapy: Molecular mechanisms of action. Eur J Pharmacol.
740:364–378. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ghosh S: Cisplatin: The first metal based
anticancer drug. Bioorg Chem. 88:1029252019. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Amable L: Cisplatin resistance and
opportunities for precision medicine. Pharmacol Res. 106:27–36.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Matsubara H, Fukuda T, Awazu Y, Nanno S,
Shimomura M, Inoue Y, Yamauchi M, Yasui T and Sumi T: PRMT1
expression predicts sensitivity to platinum-based chemotherapy in
patients with ovarian serous carcinoma. Oncol Lett. 21:1622021.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kawanishi M, Fukuda T, Shimomura M, Inoue
Y, Wada T, Tasaka R, Yasui T and Sumi T: Expression of UCP2 is
associated with sensitivity to platinum-based chemotherapy for
ovarian serous carcinoma. Oncol Lett. 15:9923–9928. 2018.PubMed/NCBI
|
|
27
|
Tasaka R, Fukuda T, Shimomura M, Inoue Y,
Wada T, Kawanishi M, Yasui T and Sumi T: TBX2 expression is
associated with platinum-sensitivity of ovarian serous carcinoma.
Oncol Lett. 15:3085–3090. 2018.PubMed/NCBI
|
|
28
|
Fukuda T, Kawanishi M, Awazu Y, Nanno S,
Shimomura M, Inoue Y, Matsubara H, Yamauchi M, Kasai M, Hashiguchi
Y, et al: Neutrophil-to-lymphocyte ratio is associated with
sensitivity to platinum-based chemotherapy and prognosis in
patients with advanced serous ovarian carcinoma. Mol Clin Oncol.
15:2172021. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Peng S and Fu Y: FYN: Emerging biological
roles and potential therapeutic targets in cancer. J Transl Med.
21:842023. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Huang C, Zhou J, Nie Y, Guo G, Wang A and
Zhu X: A new finding in the key prognosis-related proto-oncogene
FYN in hepatocellular carcinoma based on the WGCNA hub-gene
screening trategy. BMC Cancer. 22:3802022. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Lyu SC, Han DD, Li XL, Ma J, Wu Q, Dong
HM, Bai C and He Q: Fyn knockdown inhibits migration and invasion
in cholangiocarcinoma through the activated AMPK/mTOR signaling
pathway. Oncol Lett. 15:2085–2090. 2018.PubMed/NCBI
|
|
32
|
Yu J, Zhou Z, Wei Z, Wu J, OuYang J, Huang
W, He Y and Zhang C: FYN promotes gastric cancer metastasis by
activating STAT3-mediated epithelial-mesenchymal transition. Transl
Oncol. 13:1008412020. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhang X, Huang Z, Guo Y, Xiao T, Tang L,
Zhao S, Wu L, Su J, Zeng W, Huang H, et al: The phosphorylation of
CD147 by Fyn plays a critical role for melanoma cells growth and
metastasis. Oncogene. 39:4183–4197. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Dong W, Sun SJ, Qin JJ and Liu GM: Fyn
stimulates the progression of pancreatic cancer via Fyn-GluN2b-AKT
axis. Eur Rev Med Pharmacol Sci. 24:109–121. 2020.PubMed/NCBI
|
|
35
|
Zhang J, Zhao D, Zhang L, Xiao Y, Wu Q,
Wang Y, Chen J and Zhan Q: Src heterodimerically activates Lyn or
Fyn to serve as targets for the diagnosis and treatment of
esophageal squamous cell carcinoma. Sci China Life Sci.
66:1245–1263. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Elias D and Ditzel HJ: Fyn is an important
molecule in cancer pathogenesis and drug resistance. Pharmacol Res.
100:250–254. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Sakhare SS, Rao GG, Mandape SN and Pratap
S: Transcriptome profile of OVCAR3 cisplatin-resistant ovarian
cancer cell line. BMC Bioinformatics. 15:212014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Liu G, Ji L, Ke M, Ou Z, Tang N and Li Y:
miR-125a-3p is responsible for chemosensitivity in PDAC by
inhibiting epithelial-mesenchymal transition via Fyn. Biomed
Pharmacother. 106:523–531. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Noronha G, Barrett K, Boccia A, Brodhag T,
Cao J, Chow CP, Dneprovskaia E, Doukas J, Fine R, Gong X, et al:
Discovery of [7-(2,6-dichlorophenyl)-5-methylbenzo
[1,2,4]triazin-3-yl]-[4-(2-pyrrolidin-1-ylethoxy)phenyl]amine-a
potent, orally active Src kinase inhibitor with anti-tumor activity
in preclinical assays. Bioorg Med Chem Lett. 17:602–608. 2007.
View Article : Google Scholar : PubMed/NCBI
|
